Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158798 | 0.90 | SMN1; SMN2 (0.56) | DDX3XSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL164879 | 0.83 | MAPT (0.52) | SMN1; SMN2NPC1RAB9ALMNAMAPT | |
| SCHEMBL157991 | 0.81 | DDX3X (0.58) | DDX3XSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL164623 | 0.80 | KDM4E (0.54) | DDX3XSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL162693 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ALMNAMAPT | |
| SCHEMBL163898 | 0.79 | DDX3X (0.56) | DDX3XSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL159777 | 0.74 | NR1H4 (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL163582 | 0.72 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL162484 | 0.71 | HDAC8 (0.56) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL160332 | 0.70 | KDM4E (0.59) | DDX3XSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | DDX3X 3177/4885SMN1; SMN2 2105/4885NPC1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.